702681-67-2
702681-67-2 structure
- Name: CP-868388 free base
- Chemical Name: (S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-isopropyl-benzyl ester
- CAS Number: 702681-67-2
- Molecular Formula: C26H33NO5
- Molecular Weight: 439.54400
- Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
- Create Date: 2016-02-25 14:22:01
- Modify Date: 2026-07-01 17:14:16
-
CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions[1].
| Name | (S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-isopropyl-benzyl ester |
|---|---|
| Synonyms |
868388 free base
2-methyl-2-{3-[(3S)-1-({[4-(propan-2-yl)phenyl]methoxy}carbonyl)piperidin-3-yl]phenoxy}propanoic acid 1-Piperidinecboxylic acid, 3-[3-(1-cboxy-1-methylethoxy)phenyl]-, 1-[[4-(1-methylethyl)phenyl]methyl] ester, (3S) 868388 UNII-999KY5ZIGB (S)-2-(3-(1-((4-Isopropylbenzyloxy)carbonyl)piperidin-3-yl)phenoxy)-2-methylpropanoic acid (-)-868388 |
| Description | CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions[1]. |
|---|---|
| Related Catalog | |
| Target |
hPPARα:10.8 nM (Ki) hPPARγ:3.47 μM (Ki) |
| In Vitro | CP-868388 (0-1 mM) displays robust and dose-dependent recruitment of SRC-1 (EC50 of 4.7 nM) and PGC-1α peptide[1]. CP-868388 demonstrate robust and selective transcriptional activation of PPARα with an EC50 of 18 nM in HepG2 cells[1]. |
| In Vivo | CP-868388 (0-3 mg/kg; oral gavage; once daily; for 2 days; male B6/CBF1J mice) treatment shows a robust and highly significant decrease in circulating plasma triglycerides. Triglyceride lowering is dose-dependent with the greatest efficacy achieved at the 3.0 mg/kg dose, with triglyceride decreases of ~50%[1]. Animal Model: Male B6/CBF1J mice[1] Dosage: 0 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg Administration: Oral gavage; once daily; for 2 days Result: Demonstrated a robust and highly significant decrease in circulating plasma triglycerides. |
| References |
| Molecular Formula | C26H33NO5 |
|---|---|
| Molecular Weight | 439.54400 |
| Exact Mass | 439.23600 |
| PSA | 76.07000 |
| LogP | 5.50610 |
| Symbol |
GHS06, GHS09 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H410 |
| Precautionary Statements | P273-P301 + P310-P501 |
| RIDADR | UN 2811 6.1 / PGIII |